Introduction
============

Gastric cancer is one of the most frequent causes of cancer-related deaths worldwide ([@b1-or-42-01-0202]) and is the most commonly diagnosed cancer, ranking third in cancer mortality rates in Korea ([@b2-or-42-01-0202]). Early diagnosis, improved nutritional care, and new chemotherapies have led to better outcomes over the past 20 years ([@b3-or-42-01-0202]). However, chemotherapy has limited effects ([@b4-or-42-01-0202]), and targeted therapy is used only for a small subset of patients due to restricted availability of biomarkers ([@b5-or-42-01-0202],[@b6-or-42-01-0202]). Thus, studies of mechanisms contributing to gastric cancer are essential for development of new therapeutic strategies.

*HOXC10* is a member of the *HOX* genes and contributes to hind limb development ([@b7-or-42-01-0202]). In addition to its role as a developmental regulator, recent studies revealed additional roles of *HOXC10*, such as controlling the browning of white adipose tissues and regulation of the cell cycle ([@b8-or-42-01-0202],[@b9-or-42-01-0202]). In addition, recent studies have reported aberrant expression of *HOXC10* and its effects in diverse cancers. Studies in glioma, lung adenocarcinoma, osteosarcoma, and thyroid cancer demonstrated that aberrant *HOXC10* expression was correlated with poor survival outcome ([@b10-or-42-01-0202]--[@b13-or-42-01-0202]). *HOXC10* knockdown enhanced apoptosis and attenuated proliferation, metastasis, and expression of immunosuppressive genes in glioma ([@b12-or-42-01-0202]). In thyroid cancer, *HOXC10* knockdown was associated with cell cycle arrest and repression of metastasis ([@b10-or-42-01-0202]). In breast cancer, *HOXC10* was upregulated by estrogen, which recruits MLL3 and MLL4 to the estrogen response element in the *HOXC10* promoter region ([@b14-or-42-01-0202]). However, in breast cancer treated with aromatase inhibitors, resistance to the inhibitors occurred through downregulation of *HOXC10* expression mediated by hypermethylation of *HOXC10* promoter regions ([@b15-or-42-01-0202]). Another study revealed that *HOXC10* contributed to chemotherapy resistance through DNA repair by binding with cyclin-dependent kinase 7 and activating the NF-κB pathway ([@b16-or-42-01-0202]). Collectively, *HOXC10* plays roles as a transcription factor in the development and in cancer progression. Moreover, HOXC10 mediates additional functions by binding to other proteins.

Epigenetic alterations, including DNA methylation, histone modification and non-coding RNAs, are as important as genetic mutations in cancer progression and metastasis ([@b17-or-42-01-0202]). DNA methylation of promoter CpG islands interrupts binding of transcription factors, thus, repressing gene expression ([@b18-or-42-01-0202]). In cancer, numerous tumor suppressor genes are downregulated by hypermethylation, while oncogenes are upregulated by hypomethylation, at their CpG promoter sites ([@b17-or-42-01-0202],[@b18-or-42-01-0202]).

Recent studies have reported that *HOXC10* is upregulated in gastric cancer and promotes cell growth and metastasis through the MAPK ([@b19-or-42-01-0202]) or NF-κB pathway ([@b20-or-42-01-0202]). However, genetic or epigenetic changes associated with *HOXC10* overexpression in gastric cancer have yet to be identified. In addition, the target genes transcriptionally regulated by *HOXC10* overexpression are not fully understood. The aim of the present study was to investigate the epigenetic and transcriptomic alterations associated with *HOXC10* overexpression. *HOXC10* expression in gastric cancer tissues and tumorigenicity of *HOXC10 in vitro* were examined. Furthermore, it was revealed that the upregulation of H*OXC10* was regulated by DNA methylation of its promoter region. Several genes transcriptionally regulated by HOXC10 were also identified.

Materials and methods
=====================

### Public data analysis

Gene expression and DNA methylation data for gastric cancer patients were obtained from the GDC data portal (<https://portal.gdc.cancer.gov/>). Gene expression data for gastric cancer patients with survival information was downloaded from the GEO database (GSE26253) ([@b21-or-42-01-0202]).

### Clinical samples

Paired gastric tumor and normal tissue samples (n=242) were collected from Chungnam National University Hospital (CNUH; Daejeon, Korea) with informed consent obtained from all patients and among them 171 samples have clinicopathological information. The present study was approved by the Internal Review Board of CNUH.

### Cell culture, transfection and 5-aza-2′-deoxycitidine (5-aza-dC) treatment

Gastric cancer cell lines (SNU-001, SNU-005, SNU-216, SNU-016, SNU-484, SNU-520, SNU-601, SNU-620, SNU-638, SNU-668, SNU-719, AGS, KATOIII, MKN1, MKN45 and MKN74) were obtained from the Korean Cell Line Bank (<http://cellbank.snu.ac.kr/main/index.html>) and were maintained in complete RPMI-1640 and DMEM medium (Welgene, Inc., Gyeongsan-si, Korea) at 37°C in a humidified 5% CO~2~ incubator. Complete media were supplemented with 10% fetal bovine serum (FBS; Welgene, Inc.) and 1% antibiotic-antimycotic solution (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The *HOXC10* full cDNA clone was amplified by RT-PCR (primer sequences are listed in [Table SI](#SD1-or-42-01-0202){ref-type="supplementary-material"}) and inserted into the pCDH-CMV-MCS-EF1-Puro (CD510B-1) lentiviral vector. An empty vector was used as a control. For viral particle generation, cloned DNAs and lentiviral packaging Mix (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) were transfected into 293T cells using X-tremeGENE™ HP DNA Transfection reagent (Roche Diagnostics, Basel, Switzerland) in Opti-MEM media (Gibco; Thermo Fisher Scientific, Inc.). After 2 h of incubation, the media was changed to complete media. After 48 h of incubation, virus particles were collected from the supernatant. For viral infection, 2×10^5^ gastric cancer cells were added to each well of a 6-well plate and incubated overnight at 37°C. Viral supernatant was added to plated cells, and after incubation for overnight at 37°C, the media was changed to complete media. After 24 h, infected cells were selected using puromycin treatment. *HOXC10* transfection was confirmed by RT-PCR and western blot analysis. The siRNA in this study was purchased from Bioneer Corp. (Daejeon, Korea). The antisense and sense sequences of the siRNA are the following. siCST1: CUAUAACGCAGACCUCAAU and AUUGAGGUCUGCGUUAUAG. A total of 100 nM siRNA was transfected with the Lipofectamine RNAiMAX reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s instructions. One million cells were treated with 10 µM 5-aza-dC (Sigma-Aldrich; Merck KGaA) in a 100-mm dish for three days with media changes every 24 h following by harvesting.

### Reverse transcription PCR, quantitative real-time PCR and western blot analysis

Total RNA was extracted using the RNeasy Plus Mini kit (Qiagen, Venlo, The Netherlands) according to the manufacturer\'s instructions. Reverse transcription was performed using 1 µg total RNA as the template and iScript cDNA Synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA). RT-PCR assays were performed using a PCR Master Mix (MGmed, Inc., Seoul, Korea) for 5 min at 25°C, for 30 min at 42°C, for 5 min at 85°C. Quantitative real-time PCR (qPCR) reactions were performed in triplicate on a CFX96™ Real-Time PCR Detection System (Bio-Rad Laboratories) using SsoAdvanced™ Universal Inhibitor-Tolerant SYBR-Green Supermix (Bio-Rad Laboratories) for 3 min at 95°C, and 40 cycles for 20 sec at 95°C, for 20 sec at 60°C, 20 sec 72°C. The relative expression of cDNA was normalized to β-actin, quantified using the 2^−ΔΔCq^ cycle threshold method ([@b22-or-42-01-0202]), and at least three independent biological replicates were included for each reaction. Primers used for PCR were designed either manually or using the Primer3 program (<http://bioinfo.ut.ee/primer3-0.4.0/>). All primer sequences are listed in [Table SI](#SD1-or-42-01-0202){ref-type="supplementary-material"}. Cells were lysed using 2X Laemmli sample buffer \[4% SDS, 20% glycerol, 120 mM Tris-Cl (pH 6.8)\] with a protease inhibitor cocktail (Roche Diagnostics). Supernatants were collected and quantified using bovine serum albumin (BSA) (Thermo Fisher Scientific, Inc.) by Bradford assay. A total of 30 µg proteins were loaded onto 12% polyacrylamide gels, electrophoresed and transferred to a polyvinylidene difluoride (PVDF) membrane (Roche Diagnostics) and probed with the HOXC10 antibody (dilution 1:1,000; rabbit polyclonal; cat. no. ab153904; Abcam, Cambridge, MA, USA) and β-actin antibody (dilution 1:1,000; mouse monoclonal; cat. no. 061M4808; Sigma-Aldrich) at 4°C overnight. HRP-conjugated anti-rabbit and anti-mouse IgG antibodies (dilution 1:5,000; cat. nos. sc-2357 and sc-516102; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) were used as the secondary antibody at room temperature for 2 h. Bands were detected with ECL reagent (Amersham Biosciences, Buckinghamshire, UK) and scanned with a Fujifilm LAS-4000 Imaging System and analyzed using MultiGauge Software (Fujifilm, Brookvale, Australia).

### Cell proliferation, colony formation, migration and wound healing assays

Suspensions of 1.0×10^3^ cells were seeded into 96-well plates. After 24, 48, 72 or 96 h of incubation at 37°C, EZ-cytox Cell Viability Assay kit mixture (DoGen, Seoul, Korea) was added. After 1 h of incubation, the fluorescence intensity ratio from 650 to 450 nm was measured. Suspended AGS (1×10^3^) cells were added to each well of a 6-well plate and incubated at 37°C for seven days. Colony forming cells were stained using 0.5% crystal violet staining solution (Sigma-Aldrich; Merck KGaA) and counted. Transwell chambers (Corning Inc., Corning, NY, USA) were coated with fibronectin (Sigma-Aldrich; Merck KGaA). Cells were suspended in serum-free media and seeded into the upper chamber at a density of 1×10^5^ cells (MKN74) and 1.5×10^4^ cells (AGS) per well, and serum-containing media was placed into the lower chamber. After incubation at 37°C for 18--20 h, cells penetrating the pores were stained using 0.5% crystal violet staining solution (Sigma-Aldrich; Merck KGaA) and observed under a light microscope. Suspended MKN74 cells (5×10^4^) were plated into each well of Culture-Insert 2 Well in µ-Dish 35 mm (ibidi Gmbh, Martinsried, Germany). After 24 h of incubation at 37°C, cells were gently removed from the Culture-Insert using sterile tweezers. The used dish was filled with cell-free medium and observed after 24, 48 and 72 h under a light microscope.

### Bisulfite sequencing

Genomic DNA was bisulfite modified using the EZ DNA methylation kit (Zymo Research, Irvine, CA, USA) and PCR amplified. PCR products were cloned into a pGEM-T Easy vector (Promega, Madison, WI, USA) and a few clones were randomly selected for sequencing. Bisulfite-modified DNA was amplified using a primer set designed to amplify a site between +832 and +1176 relative to the transcription start site using MethPrimer (<http://www.urogene.org/cgi-bin/methprimer/meth-primer.cgi>). Primer sequences were 5′-GGGTAAAGTGAGTTTTTTTGAGATTTTTAA-3′ (forward) and 5′-CTTCCCTAATCCCTAACCCAAAATC-3′ (reverse). Methylation levels are indicated as the percentage of CpG methylated sites among all CpG sites.

### RNA sequencing and data access

The RNA sequencing library was prepared using the TruSeq RNA Sample Prep kit (Illumina, San Diego, CA, USA; <http://www.illumina.com>), and sequencing was performed using the Illumina HiSeq 2000 platform to generate 100-bp paired-end reads. Sequenced reads were mapped to the human genome (hg19) using STAR (v.2.5.1), and gene expression levels were quantified with the count module in STAR ([@b23-or-42-01-0202]). The TMM (trimmed mean of M-values)-normalized CPM (counts per million) value of each gene was set to a baseline of 1 and log~2~-transformed for further analysis (i.e., clustering, heat map drawing and correlation analysis). NGS data were deposited in the NCBI Gene Expression Omnibus (GEO) under the accession no. GSE119196. Raw sequence tags were deposited in the NCBI Short Read Archive (SRA) under the accession no. SRP159087.

### Chromatin immunoprecipitation assay

Chromatin immunoprecipitation (ChIP) was performed using Dynabeads Protein A and G (Thermo Fisher Scientific, Inc.). For ChIP-PCR/qPCR, 2.0×10^7^ cells were cross-linked with 1% formaldehyde for 10 min at 25°C. Cells were then resuspended and lysed for 10 min at 4°C with SDS lysis buffer. The lysate was aliquoted into a milliTUBE 1 ml AFA Fiber (Covaris, Inc., Woburn, MA, USA) and sonicated using a M220 Focused-ultrasonicator (Covaris, Inc.). Fragment sizes were \~200--500 bp. Samples were diluted with low-salt RIPA buffer and pre-cleared with 50 µl of Dynabeads Protein A and G for 1 h at 4°C. Primary antibodies were added to pre-cleared supernatants, and the mixtures were incubated overnight at 4°C. Antibodies used for the ChIP assay include HOXC10 (dilution 1:400; rabbit polyclonal; cat. no. ab153904; Abcam), phosphorylated RNA polymerase II (dilution 1:400; mouse monoclonal; cat. no. ab5408; Abcam), and IgG antibodies (dilution 1:1,000; cat. nos. sc-2357 and sc-516102; Santa Cruz Biotechnology, Inc.). Next, 50 µl Dynabeads Protein A and G were added to the samples, and the mixtures were incubated for 2 h at 4°C. The beads were subsequently washed with wash buffer (low-salt RIPA, high-salt RIPA, LiCl and TE). Precipitated chromatin was eluted in 200 µl elution buffer (0.1 M NaHCO3 and 1% SDS). Reverse cross-linking was performed overnight at 65°C, and chromatin was then treated with RNase A and 5M NaCl for 30 min at 37°C and proteinase K overnight at 65°C. DNA was purified using a QIAquick PCR Purification kit (Qiagen). ChIP-PCR assays were performed using PCR Master Mix and electrophoresis 1% agarose gel. ChIP-qPCR reactions were subsequently performed.

### Statistical analysis

All experiments were triplicated and data are indicated as mean ± standard deviation. Statistical analysis was performed using Student\'s t-test. A P-value \<0.05 was considered significant. The following parameters were obtained from the medical records of the 171 patients included in the study: Age, sex, histology, lymph node metastasis, tumor stage, and *Helicobacter pylori* infection status, and these parameters were compared using a Chi-square test. Statistical analysis of correlation between expression and methylation was performed using Pearson\'s correlation coefficient. All statistical analysis were performed using R statistical programming language (version 3.4.2; <http://www.r-project.org/>).

Results
=======

### HOXC10 is overexpressed and associated with poor prognosis in gastric cancer tissues

*HOXC10* is upregulated in many types of cancer. To investigate whether *HOXC10* is overexpressed in gastric cancer tissues, we used TCGA-STAD RNA-Sequencing expression dataset. *HOXC10* expression was revealed to be higher in gastric cancer tissues than in normal tissues in TCGA dataset ([Fig. 1A](#f1-or-42-01-0202){ref-type="fig"}). The relationship between *HOXC10* expression and recurrence-free survival was then investigated in gastric cancer patients from the GEO dataset (GSE26253), demonstrating that the *HOXC10* high-expression group exhibited decreased recurrence-free survival compared to the *HOXC10* low-expression group from the GEO dataset ([Fig. 1B](#f1-or-42-01-0202){ref-type="fig"}). Overexpression of *HOXC10* was validated by performing RT-qPCR on paired normal and tumor tissue samples collected from CNUH ([Fig. 1C](#f1-or-42-01-0202){ref-type="fig"}). Clinicopathological characteristics with respect to *HOXC10* expression from the CNUH dataset are summarized in [Table I](#tI-or-42-01-0202){ref-type="table"}. A significant difference in *HOXC10* expression was observed between diffuse and intestinal cancer types (P=0.039), but there was no significant difference in other parameters.

### HOXC10 promotes cell proliferation and cell migration in MKN74 and AGS cell lines

The functional effects of *HOXC10* overexpression were first investigated in gastric cancer using *in vitro* assays. RT-PCR of *HOXC10* among 16 gastric cancer cell lines illustrated that AGS and MKN74 cells expressed *HOXC10* at low levels, while SNU-216, SNU-484, KATOIII and MKN45 cells expressed *HOXC10* at high levels ([Fig. 2A](#f2-or-42-01-0202){ref-type="fig"}). Thus, AGS and MKN74 cells were selected for infection with lentiviruses ectopically expressing *HOXC10*. Overexpression of *HOXC10* in AGS and MNK74 cells after lentivirus infection was confirmed by RT-qPCR and western blot analysis ([Fig. 2B](#f2-or-42-01-0202){ref-type="fig"}). *HOXC10* overexpression increased proliferation ([Fig. 2C](#f2-or-42-01-0202){ref-type="fig"}) and colony formation ([Fig. 2D](#f2-or-42-01-0202){ref-type="fig"}) in AGS cells and increased migration in both AGS and MKN74 cells ([Fig. 2E and F](#f2-or-42-01-0202){ref-type="fig"}). Recent studies have demonstrated that overexpression of *HOXC10* promotes cell proliferation and migration in gastric cancer GC-9811P, AGS and SGC7901 cells, and *HOXC10* knockdown suppresses progression of gastric cancer in GC-9811P, SNU638 and SGC7901 cells ([@b19-or-42-01-0202],[@b20-or-42-01-0202],[@b24-or-42-01-0202]). A mouse model injected with AGS cells containing upregulated *HOXC10* exhibited increased tumor size ([@b19-or-42-01-0202]). Collectively, it was concluded that *HOXC10* overexpression promotes proliferation, colony formation and progression in gastric cancer.

### HOXC10 expression is regulated by DNA methylation in gastric cancer tissues and cells

To reveal the mechanism of *HOXC10* overexpression in gastric cancer, publicly available TCGA STAD datasets were analyzed for DNA methylation and copy number alterations. For copy number alteration, the *HOXC10* gene was altered in 1.69% of 295 cases (amplification, 1.02%; deep deletion, 0.68%) using cBioPortal (<http://www.cbioportal.org/index.do>). To determine whether methylation of *HOXC10* CpG sites affected *HOXC10* expression, we analyzed TCGA STAD 450K array dataset. It was observed that many CpG sites in the *HOXC10* gene were hypomethylated in gastric cancer compared to normal tissues ([Fig. 3A](#f3-or-42-01-0202){ref-type="fig"}). We next attempted bisulfite sequencing to determine methylation levels of *HOXC10* CpG sites. In fact, reduced methylation at 24 CpG sites of the first intronic region of *HOXC10* (Chr12: 54,379,876-54,380,219; +832 to +1176) was confirmed in three gastric cancers compared to normal tissues ([Fig. 3B](#f3-or-42-01-0202){ref-type="fig"}). The region contains the promoter region (chr12:54,380,069-54,380,128; promoter ID: HOXC10_4) obtained from a Eukaryotic promoter database (<https://epd.vital-it.ch/index.php>). Specifically, CpG residues 3, 7, 8, 13 and 16 were significantly hypomethylated in tumor tissues (P\<0.05, Student\'s t-test). By correlation analysis of DNA methylation (TCGASTAD 450K array) and gene expression (TCGA STAD RNA-seq) data, it was revealed that three CpG sites (indicated in [Fig. 3B](#f3-or-42-01-0202){ref-type="fig"}) exhibited significant negative correlations between methylation of *HOXC10* CpG sites and *HOXC10* expression (Pearson\'s correlation coefficient r=−0.594, −0.689 and −0.699) ([Fig. 3C](#f3-or-42-01-0202){ref-type="fig"}). The methylation levels and *HOXC10* expression levels were examined in three paired gastric tumor and normal tissues ([Fig. 3D](#f3-or-42-01-0202){ref-type="fig"}). When two gastric cancer cell lines (AGS and SNU-620 with low *HOXC10* expression) were treated with 5-aza-dC, an inhibitor of DNA methyltransferase, *HOXC10* expression increased 45.24-fold (AGS) and 8.79-fold (SNU-620) ([Fig. 3E](#f3-or-42-01-0202){ref-type="fig"}). These results indicate that the methylation status of CpG sites in the *HOXC10* first intronic region was important for the regulation of *HOXC10* expression in gastric cancer.

### Transcription factor HOXC10 promotes CST1 transcription

It was demonstrated that *HOXC10* was upregulated by hypomethylation of its CpG sites, and *HOXC10* overexpression contributed to the progression of gastric cancer. Since HOXC10 is a transcription factor, the functional roles of *HOXC10* overexpression were further explored in gastric cancer by identifying its target genes. Hence, RNA sequencing of ectopic *HOXC10*-overexpressing AGS cells was performed to identify target genes regulated by HOXC10. RNA-sequencing analysis confirmed overexpression of *HOXC10* in AGS cells (3.21-fold increase compared to control vector-infected cells; [Fig. 4A](#f4-or-42-01-0202){ref-type="fig"}). Three hundred and sixty-seven (upregulated) and 366 (downregulated) genes were differentially expressed in response to ectopic *HOXC10* expression \[\|log~2~ (fold-change)\| \>1.5; [Fig. 4B](#f4-or-42-01-0202){ref-type="fig"} and [Table SII](#SD1-or-42-01-0202){ref-type="supplementary-material"}\]. Five of the highly upregulated genes (*CST1, S100P, CKS2, FSCN1* and *TRIB3*) were validated in *HOXC10*-overexpressing cells compared to controls by RT-qPCR ([Fig. 4C](#f4-or-42-01-0202){ref-type="fig"}). The HOXC10 binding motif sequence predicted by the JASPAR database (<http://jaspar.genereg.net/>) was mapped to predicted promoter regions (TSS±2 kb) of RNA-seq fold-change \>1.5 genes, and 185 genes were selected (P\<0.001) ([Fig. 4D](#f4-or-42-01-0202){ref-type="fig"} and [Table SIII](#SD1-or-42-01-0202){ref-type="supplementary-material"}). By combining two different data sets (RNA-seq fold-change \>1.5 with binding motif of HOXC10 predicted by JASPAR database, and gene expression increased \>1.5-fold in TCGA dataset), 19 genes were selected as potential target genes regulated by HOXC10 ([Fig. 4E](#f4-or-42-01-0202){ref-type="fig"}). For example, *CST1* expression was significantly overexpressed in TCGA dataset ([Fig. 4F](#f4-or-42-01-0202){ref-type="fig"}). A recent study reported that *CST1* is upregulated and promotes cell proliferation in gastric cancer ([@b25-or-42-01-0202]).

Chromatin immunoprecipitation (ChIP) was then performed in cells with ectopic *HOXC10* expression. First, a ChIP assay was conducted at the *CST1* promoter region (Chr20:23,732,257-23,732,507) using the HOXC10 antibody. ChIP-PCR and ChIP-qPCR analysis demonstrated HOXC10 bound to *CST1* promoter region ([Fig. 5A](#f5-or-42-01-0202){ref-type="fig"}). Additionally, to indicate whether transcriptional machinery operated by HOXC10 binding to the *CST1* promoter region, a ChIP assay was designed at the transcription start site region of *CST1* (Chr20:23,731,473-23,731,614) with phosphorylated RNA pol II antibody. Phosphorylated RNA pol II did bind to the *CST1* transcription start site region ([Fig. 5B](#f5-or-42-01-0202){ref-type="fig"}). A ChIP assay was also performed on *S100P* (another predicted target) promoter regions and TSS regions ([Fig. 5C and D](#f5-or-42-01-0202){ref-type="fig"}). In addition, it was observed that gastric patients with high *CST1* expression exhibited decreased recurrence-free survival compared to those with low *CST1* expression ([Fig. 6A](#f6-or-42-01-0202){ref-type="fig"}). Combined analysis of *CST1* and *HOXC10* expression again confirmed that the *CST1/HOXC10* high-expression group exhibited worse recurrence-free survival than the *CST1/HOXC10* low-expression group ([Fig. 6B](#f6-or-42-01-0202){ref-type="fig"}). These results indicated that overexpression of *CST1* mediated by HOXC10 contributes to worse prognosis in gastric cancer patients.

### Knockdown of CST1 inhibits gastric cancer progression

Expression of *CST1* was upregulated in *HOXC10*-overexpressing AGS cells ([Fig. 4C](#f4-or-42-01-0202){ref-type="fig"}) and tumor tissues of the TCGA dataset. It was validated that HOXC10 regulated the expression of *CST1* by using ChIP-PCR. Gastric cancer patients with both CST1 and HOXC10 overexpression exhibited the poorest survival ([Fig. 6B](#f6-or-42-01-0202){ref-type="fig"}). Thus, the roles of *CST1* in gastric cancer progression were investigated using transient knockdown of *CST1* in *HOXC10*-overexpressing cells. The silencing of *CST1* was confirmed by RT-qPCR in AGS cells ([Fig. 7A](#f7-or-42-01-0202){ref-type="fig"}). Knockdown of *CST1* inhibited cell proliferation ([Fig. 7B](#f7-or-42-01-0202){ref-type="fig"}) and colony formation ([Fig. 7C](#f7-or-42-01-0202){ref-type="fig"}) in AGS cells. *CST1* expression was upregulated in *HOXC10*-overexpressing MKN74 cells and downregulated in *CST1*-silencing MKN74 cells ([Fig. 7D](#f7-or-42-01-0202){ref-type="fig"}). Knockdown of *CST1* suppressed the migration ability of MKN74 cells ([Fig. 7E](#f7-or-42-01-0202){ref-type="fig"}). As another downstream target of HOXC10, *S100P* was also assessed, and it was revealed that knockdown of *S100P* suppressed cell proliferation and reduced colony size in AGS cells ([Fig. S1](#SD1-or-42-01-0202){ref-type="supplementary-material"}). *CST1* and *S100P* were selected for further validation based on previous studies revealing the role of those two genes in gastric carcinogenesis. For example, *CST1* was revealed to increase cell proliferation ([@b25-or-42-01-0202]) and *S100P* to regulate cell proliferation ([@b26-or-42-01-0202]) and colony formation ([@b27-or-42-01-0202]) in gastric cancer; these two genes exhibited oncogenic roles in other cancers as well ([@b28-or-42-01-0202]--[@b33-or-42-01-0202]). Altogether, *CST1* regulated by HOXC10 contributes to gastric cancer development, and these two genes could be potential prognostic markers for gastric cancer.

Discussion
==========

Aberrant overexpression of homeodomain-containing gene 10 (*HOXC10*) and its role in cancer progression has been reported in many different cancers ([@b10-or-42-01-0202]--[@b14-or-42-01-0202]). Recently, a few studies have shown that *HOXC10* is overexpressed in gastric cancer and that its overexpression promotes cell growth and migration with activation of MAPK and NF-κB pathways ([@b19-or-42-01-0202],[@b20-or-42-01-0202]). Moreover, *HOXC10* expression is correlated with EMT marker genes (*SOX10* and *FGBP1*) ([@b34-or-42-01-0202]). We recognized that *TMEM41A* is upregulated in gastric cancer, especially metastatic and advanced tumors, and contributed to poor prognosis. *In vitro* and *in vivo* assay showed that *TMEM41A* has effects on the migration ability of gastric cancer ([@b35-or-42-01-0202]). We investigated expression of *TMEM41A* with our RNA-sequencing data; however, there were no significant differences in the expression level. This study was associated with other mechanisms in metastasis. However, mechanism of *HOXC10* overexpression in gastric cancer are not yet known. In the present study, we demonstrated that hypomethylation of *HOXC10* CpG sites is one mechanism for aberrant overexpression of *HOXC10* in gastric cancer. The CpG sites are located at the *HOXC10* first intron and include a promoter retrieved from a eukaryotic promoter database. Although bisulfite sequencing was performed on a partial region of many of the CpG sites and a few of the tissue samples, the results showed significant correlation between the levels of both DNA methylation and *HOXC10* expression.

*HOXC10* belongs to the HOX family of transcription factors, which are major regulators of organ development and cellular differentiation during animal development. However, recent studies have shown non-transcriptional interactions for Hox proteins in additional molecular processes, such as mRNA translation, DNA repair and initiation of DNA replication ([@b36-or-42-01-0202]). For example, in breast cancer, *HOXC10* induces chemotherapy resistance by binding to CDK7 and enhancing homologous recombination DNA repair processes ([@b16-or-42-01-0202]). In this regard, it is of interest to reveal how overexpressed *HOXC10* exerts its functions in gastric cancer cells, that is, transcriptionally or non-transcriptionally.

In this study, we primarily focused on the role of HOXC10 as a transcriptional regulator. By analyzing RNA-seq and ChIP assays, we identified *CST1* as one of the 19 targets genes regulated by HOXC10 in gastric cancer. *CST1* is a cysteine protease inhibitor belonging to the cystatin superfamily. Recent studies have shown that *CST1* is upregulated and contributes to cancer progression in multiple neoplasms, including gastric ([@b25-or-42-01-0202]), breast ([@b31-or-42-01-0202]), non-small cell lung cancer (NSCLC) ([@b30-or-42-01-0202]), colorectal ([@b33-or-42-01-0202]) and pancreatic cancer ([@b32-or-42-01-0202]). In colorectal cancer, cathepsin B is associated with invasion of colon cancer cells by extracellular matrix degradation. CST1 attenuates inhibition of cathepsin B by CST3 through binding to CST3 ([@b33-or-42-01-0202]), and sustenance of cathepsin B by CST1 promotes cancer development by inhibiting cellular senescence ([@b37-or-42-01-0202]). Additionally, CST1 is a mediator of bone metastasis ([@b38-or-42-01-0202],[@b39-or-42-01-0202]). However, as mechanisms of *CST1* are unclear in gastric cancer, further studies are required. Overexpression of cytokeratin associated protein (*CAP*) downregulated NF-κB activity and decreased expression of many of its target genes, including *CST1* ([@b40-or-42-01-0202]). Knockdown of *CST1* by miRNA let-7d reduces cell proliferation through phosphorylation of the NF-κB p65 subunit in colorectal cancer ([@b41-or-42-01-0202]). Gene-set enrichment analysis using our RNA-seq data revealed that the NF-κB pathway was activated ([Fig. S2A](#SD1-or-42-01-0202){ref-type="supplementary-material"}), consistent with a previous study reporting that *HOXC10* activates NF-κB in gastric cancer and breast cancer ([@b16-or-42-01-0202],[@b20-or-42-01-0202]). We suppose that *HOXC10* and *CST1* promote cancer progression through the NF-κB pathway. *TLR4* is one of the NF-κB pathway genes with *HOXC10* binding motifs and is overexpressed in cells overexpressing *HOXC10* (0.82-log~2~FC) ([Fig. S1B](#SD1-or-42-01-0202){ref-type="supplementary-material"}).

In conclusion, *HOXC10* expression is upregulated in gastric cancer through DNA demethylation, and *HOXC10* overexpression increases proliferation and migration of gastric cancer cells. *CST1* was identified as one of the target genes regulated by HOXC10 in gastric cancer. *CST1* knockdown represses tumorigenicity of gastric cancer cells. We propose *HOXC10* and *CST1* as useful prognostic markers or therapeutic targets for gastric cancer.
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![*HOXC10* overexpression promotes gastric cancer progression. (A) Comparison of *HOXC10* expression between normal and tumor gastric tissues (TCGA datasets). (B) Kaplan-Meyer plot of two groups of gastric cancer patients classified by *HOXC10* expression (GSE26253. N=432; P=0.029, log-rank test; Hazard ratio=1.4, P=0.0295, cox-regression test). Red, high-expression group; blue, low-expression group. (C) Relative *HOXC10* mRNA levels in paired tumor and normal gastric tissues collected at CNUH by RT-qPCR. *HOXC10*, homeodomain-containing gene 10; CNUH, Chungnam National University Hospital.](OR-42-01-0202-g00){#f1-or-42-01-0202}

![*HOXC10* increases gastric cancer cell proliferation and migration. (A) *HOXC10* mRNA expression in human gastric cancer cell lines by RT-PCR. (B) RT-qPCR and western blot analysis of HOXC10 after ectopic *HOXC10* overexpression in AGS and MKN74 cells. (C) Proliferation assay (CCK-8) after *HOXC10* overexpression in AGS cells. (D) Colony formation assay after *HOXC10* overexpression in AGS cells. (E) Migration assay after *HOXC10* overexpression in AGS and MKN74 cells. (F) Wound healing assay after *HOXC10* overexpression in MKN74 cells. Scale bar, 200 µm. For all, \*P\<0.05; \*\*P\<0.01; \*\*\*P\<0.001, Student\'s t-test. The error bars represent the mean ± SD. *HOXC10*, homeodomain-containing gene 10; CCK-8, Cell Counting Kit-8.](OR-42-01-0202-g01){#f2-or-42-01-0202}

![Methylation profiling of *HOXC10* in gastric tissues and cell lines. (A) Methylation status of *HOXC10* CpG sites from TCGA 450K array dataset. (B) Result of bisulfite sequencing of 24 CpG sites in the *HOXC10* first intron region (N, normal tissue; T, tumor tissue). (C) Significant negative correlation between DNA methylation and mRNA expression in three CpG sites (Pearson\'s correlation coefficient, Student\'s t-test). (D) Comparison between methylation levels from bisulfite sequencing and *HOXC10* expression levels in paired gastric tumor and normal tissues. (E) Restoration of *HOXC10* expression by 5-azacytidine treatment in AGS and SNU-620 cells (\*\*P\<0.01, Student\'s t-test. The error bars represent the mean ± SD). *HOXC10*, homeodomain-containing gene 10.](OR-42-01-0202-g02){#f3-or-42-01-0202}

![Selection of a direct target of HOXC10 by RNA-sequencing data analysis. (A) *HOXC10* expression levels from RNA-sequencing in response to ectopic *HOXC10* overexpression in AGS cells. (B) Scatter plot of expression level of 733 genes (\|log2 FC\| \>1.5) from RNA-seq. (C) Validation of upregulated genes in RNA-sequencing results by RT-qPCR (\*\*P\<0.01, \*\*\*P\<0.001; Student\'s t-test. The error bars represent the mean ± SD). (D) Predicted HOXC10 binding motif site sequence from the database JASPAR. (E) Predicted target genes via RNA-sequencing, predicted binding sites and TCGA expression dataset. (F) Comparison of *CST1* expression in normal and tumor gastric tissues (TCGA datasets). *HOXC10*, homeodomain-containing gene 10.](OR-42-01-0202-g03){#f4-or-42-01-0202}

![Validation of *CST1* and *S100P* as direct target genes of HOXC10. (A) Ascertainment of HOXC10 binding to the *CST1* promoter region (Chr20:23,732,257-23,732,507) using ChIP-PCR and ChIP-qPCR. (B) Ascertainment of phosphorylated RNA polymerase II (phospho-Ser5) binding to the *CST1* TSS region (Chr20: 23,731,473-23,731,614) using ChIP-PCR and ChIP-qPCR. (C) Ascertainment of HOXC10 binding to the *S100P* promoter region (6,694,618-6,694,740) using ChIP-PCR and ChIP-qPCR. (D) Ascertainment of phosphorylated RNA polymerase II (phospho-Ser5) binding to the *S100P* TSS region (Chr4: 6,695,457-6,695,617) using ChIP-PCR and ChIP-qPCR. For all, \*P\<0.05; \*\*\*P\<0.001, Student\'s t-test. The error bars represent the mean ± SD. *HOXC10*, homeodomain-containing gene 10.](OR-42-01-0202-g04){#f5-or-42-01-0202}

![*CST1* and *HOXC10* expression are associated with clinical outcome. (A) Kaplan-Meier plot of two groups of gastric cancer patients classified by *CST1* expression (GSE26253. n=432; P=0.047, log-rank test; Hazard ratio=1.35, P=0.048, cox-regression test). Red, high-expression group, blue, low-expression group. (B) Kaplan-Meier plot of four groups of gastric cancer patients classified by *HOXC10* and *CST1* expression (GSE26253; n=432; P=0.033. A log-rank test was performed to assess whether the survival curves of the four groups have similar distributions or not). *HOXC10*, homeodomain-containing gene 10.](OR-42-01-0202-g05){#f6-or-42-01-0202}

![Silencing of *CST1* suppresses gastric cancer cell proliferation and migration. (A) RT-qPCR of *CST1* in *CST1*-silencing AGS cells. (B) Proliferation assay (CCK-8) in *CST1*-silencing AGS cells. (C) Colony formation assay in *CST1*-silencing AGS cells. (D) RT-qPCR of *CST1* in *HOXC10*-overexpressing (siControl) and *CST1*-silencing MKN74 cells. (E) Migration assay in *CST1* silencing MKN74 cells. For all, \*P\<0.05; \*\*P\<0.01; \*\*\*P\<0.001, Student\'s t-test. The error bars represent the mean ± SD. *HOXC10*, homeodomain-containing gene 10; CCK-8, Cell Counting Kit-8.](OR-42-01-0202-g06){#f7-or-42-01-0202}

###### 

Clinicopathological characteristics by *HOXC10* expression in gastric cancer patients.

                                     Gastric tumors with increased relative *HOXC10* expression           
  ---------------------------------- ------------------------------------------------------------ ------- -------------------------------------------------------
  Mean patient age (in years ± SD)   60±12                                                        59±14   0.9270
  Sex                                                                                                     0.4769
    Male                             62                                                           50      
    Female                           36                                                           23      
  Lauren\'s classification                                                                                0.0386^[a](#tfn1-or-42-01-0202){ref-type="table-fn"}^
    Intestinal                       23                                                           26      
    Diffuse                          69                                                           38      
    Mixed                              6                                                            8     
    No information                     0                                                            1     
  Tumor progression                                                                                       0.8769
    EGC                              10                                                             7     
    AGC                              87                                                           66      
    No information                     1                                                            0     
  Stage                                                                                                   0.4522
    I                                17                                                           15      
    II                               23                                                           19      
    III                              27                                                           21      
    IV                               31                                                           18      
  *Helicobacter pylori* infection                                                                         0.7343
    Positive                         59                                                           43      
    Negative                         23                                                           19      
    No information                   16                                                           18      

P\<0.05. *HOXC10*, homeodomain-containing gene 10.
